Infliximab biosimilar (Bionovis/The Instituto Vital Brazil)

英夫利西单抗生物类似药（Bionovis/The Instituto Vital Brazil）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfliximab biosimilar (Bionovis/The Instituto Vital Brazil)

Drug Alias Name英夫利西单抗生物仿制药（Bionovis/The Instituto Vital Brazil）Infliximab (Bionovis/The Instituto Vital Brazil)Infliximabum (Bionovis/The Instituto Vital Brazil)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesBionovis The Instituto Vital Brazil

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[6]

Inactive IndicationsN/A

Other Information

ATC CodeL04AB02